LAVA Therapeutics NV held its annual general meeting of shareholders on June 11, 2025. During the meeting, several proposals were voted upon and approved. These included the adoption of the Dutch statutory annual accounts for the financial year 2024, the reappointment of James Noble and Jay Backstrom as non-executive directors, the extension of authorization for the board to acquire shares, the appointment of KPMG Accountants N.V. as the external auditor for 2025, and the ratification of KPMG LLP as the independent registered public accounting firm for the same year. Additionally, the release of board members from liability for the exercise of their duties during the financial year 2024 was approved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。